References
Ahrens, J., Demir, R., Leuwer, M., de la Roche, J., Krampfl, K., Foadi,
N., . . . Haeseler, G. (2009). The Nonpsychotropic Cannabinoid
Cannabidiol Modulates and Directly Activates Alpha-1 and Alpha-1-Beta
Glycine Receptor Function. Pharmacology, 83 (4), 217-222.
doi:10.1159/000201556
Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural
Update Review. (2016). Cannabis and Cannabinoid Research, 1 (1),
22-30. doi:10.1089/can.2015.0005
Aviello, G., Romano, B., Borrelli, F., Capasso, R., Gallo, L.,
Piscitelli, F., . . . Izzo, A. A. (2012). Chemopreventive effect of the
non-psychotropic phytocannabinoid cannabidiol on experimental colon
cancer. Journal of Molecular Medicine, 90 (8), 925-934.
doi:10.1007/s00109-011-0856-x
Bakas, T., van Nieuwenhuijzen, P. S., Devenish, S. O., McGregor, I. S.,
Arnold, J. C., & Chebib, M. (2017). The direct actions of cannabidiol
and 2-arachidonoyl glycerol at GABAA receptors. Pharmacological
Research, 119 , 358-370.
doi:https://doi.org/10.1016/j.phrs.2017.02.022
Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders
in the 21st century. Dialogues Clin Neurosci, 17 (3), 327-335.
doi:10.31887/DCNS.2015.17.3/bbandelow
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D.
C. G., De Martinis, B. S., Kapczinski, F., . . . Crippa, J. A. S.
(2011). Cannabidiol Reduces the Anxiety Induced by Simulated Public
Speaking in Treatment-Naive Social Phobia Patients.Neuropsychopharmacology, 36 (6), 1219-1226. doi:10.1038/npp.2011.6
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E.,
Brandi, I., . . . Di Marzo, V. (2001). Molecular targets for cannabidiol
and its synthetic analogues: effect on vanilloid VR1 receptors and on
the cellular uptake and enzymatic hydrolysis of anandamide.British journal of pharmacology, 134 (4), 845-852.
doi:https://doi.org/10.1038/sj.bjp.0704327
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R.
(2015). Cannabidiol as a Potential Treatment for Anxiety Disorders.Neurotherapeutics, 12 (4), 825-836. doi:10.1007/s13311-015-0387-1
Bloechl-Daum, B., Deuson, R. R., Mavros, P., Hansen, M., & Herrstedt,
J. (2006). Delayed Nausea and Vomiting Continue to Reduce Patients’
Quality of Life After Highly and Moderately Emetogenic Chemotherapy
Despite Antiemetic Treatment. Journal of Clinical Oncology,
24 (27), 4472-4478. doi:10.1200/jco.2006.05.6382
Boggs, D. L., Surti, T., Gupta, A., Gupta, S., Niciu, M., Pittman, B., .
. . Ranganathan, M. (2018). The effects of cannabidiol (CBD) on
cognition and symptoms in outpatients with chronic schizophrenia a
randomized placebo controlled trial. Psychopharmacology (Berl),
235 (7), 1923-1932. doi:10.1007/s00213-018-4885-9
Bujak, J. K., Kosmala, D., Szopa, I. M., Majchrzak, K., & Bednarczyk,
P. (2019). Inflammation, Cancer and Immunity—Implication of TRPV1
Channel. Frontiers in Oncology, 9 (1087).
doi:10.3389/fonc.2019.01087
Burstein, S. (2015). Cannabidiol (CBD) and its analogs: a review of
their effects on inflammation. Bioorganic & Medicinal Chemistry,
23 (7), 1377-1385. doi:https://doi.org/10.1016/j.bmc.2015.01.059
Campos, A. C., Ferreira, F. R., & Guimarães, F. S. (2012). Cannabidiol
blocks long-lasting behavioral consequences of predator threat stress:
Possible involvement of 5HT1A receptors. Journal of Psychiatric
Research, 46 (11), 1501-1510.
doi:https://doi.org/10.1016/j.jpsychires.2012.08.012
Capano, A., Weaver, R., & Burkman, E. (2020). Evaluation of the effects
of CBD hemp extract on opioid use and quality of life indicators in
chronic pain patients: a prospective cohort study. Postgraduate
Medicine, 132 (1), 56-61. doi:10.1080/00325481.2019.1685298
Cathy M. Russo, M., & William G. Brose, M. (1998). Chronic Pain.Annual Review of Medicine, 49 (1), 123-133.
doi:10.1146/annurev.med.49.1.123
Catterall, W. A. (2017). Forty Years of Sodium Channels: Structure,
Function, Pharmacology, and Epilepsy. Neurochemical Research,
42 (9), 2495-2504. doi:10.1007/s11064-017-2314-9
Chu Sin Chung, P., & Kieffer, B. L. (2013). Delta opioid receptors in
brain function and diseases. Pharmacology & Therapeutics,
140 (1), 112-120.
doi:https://doi.org/10.1016/j.pharmthera.2013.06.003
ClinicalTrials. gov. Retrieved from https://clinicaltrials.gov/
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L.,
Duran, F. L. S., Martin-Santos, R., . . . Hallak, J. E. C. (2011).
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized
social anxiety disorder: a preliminary report. Journal of
Psychopharmacology, 25 (1), 121-130. doi:10.1177/0269881110379283
D’Souza, D. C., Cortes-Briones, J., Creatura, G., Bluez, G., Thurnauer,
H., Deaso, E., . . . Skosnik, P. D. (2019). Efficacy and safety of a
fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of
cannabis withdrawal and dependence in men: a double-blind,
placebo-controlled, parallel group, phase 2a single-site randomised
controlled trial. The Lancet Psychiatry, 6 (1), 35-45.
doi:10.1016/S2215-0366(18)30427-9
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno,
T., Petrosino, S., . . . Di Marzo, V. (2011). Effects of cannabinoids
and cannabinoid-enriched Cannabis extracts on TRP channels and
endocannabinoid metabolic enzymes. British journal of
pharmacology, 163 (7), 1479-1494.
doi:https://doi.org/10.1111/j.1476-5381.2010.01166.x
De Petrocellis, L., Ligresti, A., Schiano Moriello, A., Iappelli, M.,
Verde, R., Stott, C. G., . . . Di Marzo, V. (2013). Non-THC cannabinoids
inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic
effects and underlying mechanisms. British journal of
pharmacology, 168 (1), 79-102.
doi:https://doi.org/10.1111/j.1476-5381.2012.02027.x
De Petrocellis, L., Orlando, P., Moriello, A. S., Aviello, G., Stott,
C., Izzo, A. A., & Di Marzo, V. (2012). Cannabinoid actions at TRPV
channels: effects on TRPV3 and TRPV4 and their potential relevance to
gastrointestinal inflammation. Acta Physiologica, 204 (2),
255-266. doi:https://doi.org/10.1111/j.1748-1716.2011.02338.x
De Petrocellis, L., Vellani, V., Schiano-Moriello, A., Marini, P.,
Magherini, P. C., Orlando, P., & Di Marzo, V. (2008). Plant-Derived
Cannabinoids Modulate the Activity of Transient Receptor Potential
Channels of Ankyrin Type-1 and Melastatin Type-8. Journal of
Pharmacology and Experimental Therapeutics, 325 (3), 1007-1015.
doi:10.1124/jpet.107.134809
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout,
R., . . . Wright, S. (2017). Trial of Cannabidiol for Drug-Resistant
Seizures in the Dravet Syndrome. New England Journal of Medicine,
376 (21), 2011-2020. doi:10.1056/NEJMoa1611618
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan,
J., . . . Cilio, M. R. (2016). Cannabidiol in patients with
treatment-resistant epilepsy: an open-label interventional trial.The Lancet Neurology, 15 (3), 270-278.
doi:https://doi.org/10.1016/S1474-4422(15)00379-8
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E.
C., Privitera, M., . . . Zuberi, S. M. (2018). Effect of Cannabidiol on
Drop Seizures in the Lennox–Gastaut Syndrome. New England Journal
of Medicine, 378 (20), 1888-1897. doi:10.1056/NEJMoa1714631
Di Marzo, V. (2008). The endocannabinoid system in obesity and type 2
diabetes. Diabetologia, 51 (8), 1356.
doi:10.1007/s00125-008-1048-2
Di Marzo, V., Bifulco, M., & De Petrocellis, L. (2004). The
endocannabinoid system and its therapeutic exploitation. Nature
Reviews Drug Discovery, 3 (9), 771-784. doi:10.1038/nrd1495
Dunlop, B. W., & Nemeroff, C. B. (2007). The Role of Dopamine in the
Pathophysiology of Depression. Archives of General Psychiatry,
64 (3), 327-337. doi:10.1001/archpsyc.64.3.327
Duran, M., Perez, E., Abanades, S., Vidal, X., Saura, C., Majem, M., . .
. Capella, D. (2010). Preliminary efficacy and safety of an oromucosal
standardized cannabis extract in chemotherapy-induced nausea and
vomiting. Br J Clin Pharmacol, 70 (5), 656-663.
doi:10.1111/j.1365-2125.2010.03743.x
Elmes, M. W., Kaczocha, M., Berger, W. T., Leung, K., Ralph, B. P.,
Wang, L., . . . Deutsch, D. G. (2015). Fatty Acid-binding Proteins
(FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and
Cannabidiol (CBD)*. Journal of Biological Chemistry, 290 (14),
8711-8721. doi:https://doi.org/10.1074/jbc.M114.618447
Epidiolex. Retrieved from
https://www.gwpharm.com/healthcare-professionals
Epilepsy Retrieved from
https://www.who.int/news-room/fact-sheets/detail/epilepsy
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De
Filippis, D., . . . Steardo, L. (2011). Cannabidiol Reduces Aβ-Induced
Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ
Involvement. PLoS One, 6 (12), e28668.
doi:10.1371/journal.pone.0028668
Fagundo, A. B., de la Torre, R., Jiménez-Murcia, S., Agüera, Z., Pastor,
A., Casanueva, F. F., . . . Fernández-Aranda, F. (2013). Modulation of
the Endocannabinoids N-Arachidonoylethanolamine (AEA) and
2-Arachidonoylglycerol (2-AG) on Executive Functions in Humans.PLoS One, 8 (6), e66387. doi:10.1371/journal.pone.0066387
FDA Approves New Indication for Drug Containing an Active Ingredient
Derived from Cannabis to Treat Seizures in Rare Genetic Disease.
Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H.,
Elger, C. E., . . . Wiebe, S. (2014). ILAE Official Report: A practical
clinical definition of epilepsy. Epilepsia, 55 (4), 475-482.
doi:https://doi.org/10.1111/epi.12550
Fisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E.,
Jansen, F. E., . . . Zuberi, S. M. (2017). Operational classification of
seizure types by the International League Against Epilepsy: Position
Paper of the ILAE Commission for Classification and Terminology.Epilepsia, 58 (4), 522-530.
doi:https://doi.org/10.1111/epi.13670
Freedman, R. (2003). Schizophrenia. New England Journal of
Medicine, 349 (18), 1738-1749. doi:10.1056/NEJMra035458
Freitas-Ferrari, M. C., Hallak, J. E. C., Trzesniak, C., Filho, A. S.,
Machado-de-Sousa, J. P., Chagas, M. H. N., . . . Crippa, J. A. S.
(2010). Neuroimaging in social anxiety disorder: A systematic review of
the literature. Progress in Neuro-Psychopharmacology and
Biological Psychiatry, 34 (4), 565-580.
doi:https://doi.org/10.1016/j.pnpbp.2010.02.028
Gallily, R., Even-Chena, T., Katzavian, G., Lehmann, D., Dagan, A., &
Mechoulam, R. (2003). Gamma-irradiation enhances apoptosis induced by
cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60
myeloblastic leukemia cells. Leuk Lymphoma, 44 (10), 1767-1773.
doi:10.1080/1042819031000103917
Gharedaghi, M. H., Seyedabadi, M., Ghia, J.-E., Dehpour, A. R., &
Rahimian, R. (2014). The role of different serotonin receptor subtypes
in seizure susceptibility. Experimental Brain Research, 232 (2),
347-367. doi:10.1007/s00221-013-3757-0
Goddard, A. W., Ball, S. G., Martinez, J., Robinson, M. J., Yang, C. R.,
Russell, J. M., & Shekhar, A. (2010). Current perspectives of the roles
of the central norepinephrine system in anxiety and depression.Depression and Anxiety, 27 (4), 339-350.
doi:https://doi.org/10.1002/da.20642
Gottesmann, C. (2002). GABA mechanisms and sleep. Neuroscience,
111 (2), 231-239.
doi:https://doi.org/10.1016/S0306-4522(02)00034-9
Granja, A. G., Carrillo-Salinas, F., Pagani, A., Gómez-Cañas, M., Negri,
R., Navarrete, C., . . . Muñoz, E. (2012). A Cannabigerol Quinone
Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis.Journal of Neuroimmune Pharmacology, 7 (4), 1002-1016.
doi:10.1007/s11481-012-9399-3
Grimison, P., Mersiades, A., Kirby, A., Lintzeris, N., Morton, R.,
Haber, P., . . . Stockler, M. (2020). Oral THC:CBD cannabis extract for
refractory chemotherapy-induced nausea and vomiting: a randomised,
placebo-controlled, phase II crossover trial. Annals of Oncology,
31 (11), 1553-1560.
doi:https://doi.org/10.1016/j.annonc.2020.07.020
Hallak, J. E. C., Machado-de-Sousa, J. P., Crippa, J. A. S., Sanches, R.
F., Trzesniak, C., Chaves, C., . . . Zuardi, A. W. (2010). Performance
of schizophrenic patients in the Stroop Color Word Test and
electrodermal responsiveness after acute administration of cannabidiol
(CBD). Brazilian Journal of Psychiatry, 32 , 56-61.
Hammell, D. C., Zhang, L. P., Ma, F., Abshire, S. M., McIlwrath, S. L.,
Stinchcomb, A. L., & Westlund, K. N. (2016). Transdermal cannabidiol
reduces inflammation and pain-related behaviours in a rat model of
arthritis. European Journal of Pain, 20 (6), 936-948.
doi:10.1002/ejp.818
Haustrate, A., Prevarskaya, N., & Lehen’kyi, V. y. (2020). Role of the
TRPV Channels in the Endoplasmic Reticulum Calcium Homeostasis.Cells, 9 (2), 317.
Hillard, C. J. (2015). The Endocannabinoid Signaling System in the CNS:
A Primer. Int Rev Neurobiol, 125 , 1-47.
doi:10.1016/bs.irn.2015.10.001
Hillard, C. J. (2018). Circulating Endocannabinoids: From Whence Do They
Come and Where are They Going? Neuropsychopharmacology, 43 (1),
155-172. doi:10.1038/npp.2017.130
Hsiao, Y.-T., Yi, P.-L., Li, C.-L., & Chang, F.-C. (2012). Effect of
cannabidiol on sleep disruption induced by the repeated combination
tests consisting of open field and elevated plus-maze in rats.Neuropharmacology, 62 (1), 373-384.
doi:https://doi.org/10.1016/j.neuropharm.2011.08.013
Jacobsson, S. O. P., Rongård, E., Stridh, M., Tiger, G., & Fowler, C.
J. (2000). Serum-dependent effects of tamoxifen and cannabinoids upon C6
glioma cell viability. Biochemical Pharmacology, 60 (12),
1807-1813. doi:https://doi.org/10.1016/S0006-2952(00)00492-5
Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott,
C., Bell, J. D., . . . Tan, G. D. (2016). Efficacy and Safety of
Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters
in Patients With Type 2 Diabetes: A Randomized, Double-Blind,
Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care,
39 (10), 1777-1786. doi:10.2337/dc16-0650
Jadoon, K. A., Tan, G. D., & O’Sullivan, S. E. (2017). A single dose of
cannabidiol reduces blood pressure in healthy volunteers in a randomized
crossover study. JCI Insight, 2 (12).
doi:10.1172/jci.insight.93760
Jeong, S., Yun, H. K., Jeong, Y. A., Jo, M. J., Kang, S. H., Kim, J. L.,
. . . Lee, D.-H. (2019). Cannabidiol-induced apoptosis is mediated by
activation of Noxa in human colorectal cancer cells. Cancer
Letters, 447 , 12-23.
doi:https://doi.org/10.1016/j.canlet.2019.01.011
Johal, H., Devji, T., Chang, Y., Simone, J., Vannabouathong, C., &
Bhandari, M. (2020). Cannabinoids in Chronic Non-Cancer Pain: A
Systematic Review and Meta-Analysis. Clinical Medicine Insights:
Arthritis and Musculoskeletal Disorders, 13 , 1179544120906461.
doi:10.1177/1179544120906461
Johnson, E. L. (2019). Seizures and Epilepsy. Medical Clinics of
North America, 103 (2), 309-324.
doi:https://doi.org/10.1016/j.mcna.2018.10.002
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D.,
Potts, R., & Fallon, M. T. (2010). Multicenter, double-blind,
randomized, placebo-controlled, parallel-group study of the efficacy,
safety, and tolerability of THC:CBD extract and THC extract in patients
with intractable cancer-related pain. J Pain Symptom Manage,
39 (2), 167-179. doi:10.1016/j.jpainsymman.2009.06.008
Kalso, E., Edwards, J. E., Moore, R. A., & McQuay, H. J. (2004).
Opioids in chronic non-cancer pain: systematic review of efficacy and
safety. Pain, 112 (3), 372-380.
doi:https://doi.org/10.1016/j.pain.2004.09.019
Kaplan, J. S., Stella, N., Catterall, W. A., & Westenbroek, R. E.
(2017). Cannabidiol attenuates seizures and social deficits in a mouse
model of Dravet syndrome. Proceedings of the National Academy of
Sciences, 114 (42), 11229-11234. doi:10.1073/pnas.1711351114
Kaumann, A. J., & Levy, F. O. (2006). 5-hydroxytryptamine receptors in
the human cardiovascular system. Pharmacol Ther, 111 (3), 674-706.
doi:10.1016/j.pharmthera.2005.12.004
Kenyon, J., Liu, W., & Dalgleish, A. (2018). Report of Objective
Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic
Cannabidiol. Anticancer Research, 38 (10), 5831-5835.
doi:10.21873/anticanres.12924
Kesner, A. J., & Lovinger, D. M. (2020). Cannabinoids, Endocannabinoids
and Sleep. Frontiers in Molecular Neuroscience, 13 (125).
doi:10.3389/fnmol.2020.00125
Kevin P. Hill, 2,* Matthew D. Palastro,1 Brian Johnson,3 and Joseph W.
Ditre4. (2017). Cannabis and Pain: A Clinical Review. Cannabis and
Cannabinoid Research, 2 (1), 96-104. doi:10.1089/can.2017.0017
Kicman, A., & Toczek, M. (2020). The Effects of Cannabidiol, a
Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in
Health and Disease. International Journal of Molecular Sciences,
21 (18). doi:ARTN 6740
10.3390/ijms21186740
Kremer, M., Salvat, E., Muller, A., Yalcin, I., & Barrot, M. (2016).
Antidepressants and gabapentinoids in neuropathic pain: Mechanistic
insights. Neuroscience, 338 , 183-206.
doi:https://doi.org/10.1016/j.neuroscience.2016.06.057
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan-Wright, E.
M. (2015). Cannabidiol is a negative allosteric modulator of the
cannabinoid CB1 receptor. British journal of pharmacology,
172 (20), 4790-4805. doi:https://doi.org/10.1111/bph.13250
Lee, C.-Y., Wey, S.-P., Liao, M.-H., Hsu, W.-L., Wu, H.-Y., & Jan,
T.-R. (2008). A comparative study on cannabidiol-induced apoptosis in
murine thymocytes and EL-4 thymoma cells. International
Immunopharmacology, 8 (5), 732-740.
doi:https://doi.org/10.1016/j.intimp.2008.01.018
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W.,
Hoyer, C., . . . Koethe, D. (2012). Cannabidiol enhances anandamide
signaling and alleviates psychotic symptoms of schizophrenia.Translational Psychiatry, 2 (3), e94-e94. doi:10.1038/tp.2012.15
Leweke, F. M., Rohleder, C., Gerth, C. W., Hellmich, M., Pukrop, R., &
Koethe, D. (2021). Cannabidiol and Amisulpride Improve Cognition in
Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled,
Randomized Clinical Trial. Frontiers in Pharmacology, 12 (618).
doi:10.3389/fphar.2021.614811
Ligresti, A., Bisogno, T., Matias, I., De Petrocellis, L., Cascio, M.
G., Cosenza, V., . . . Di Marzo, V. (2003). Possible endocannabinoid
control of colorectal cancer growth. Gastroenterology, 125 (3),
677-687. doi:https://doi.org/10.1016/S0016-5085(03)00881-3
Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H.,
Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019). Cannabidiol
presents an inverted U-shaped dose-response curve in a simulated public
speaking test. Brazilian Journal of Psychiatry, 41 , 9-14.
Linares, I. M. P., Guimaraes, F. S., Eckeli, A., Crippa, A. C. S.,
Zuardi, A. W., Souza, J. D. S., . . . Crippa, J. A. S. (2018). No Acute
Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A
Randomized, Double-Blind, Placebo-Controlled, Crossover Study.Frontiers in Pharmacology, 9 (315). doi:10.3389/fphar.2018.00315
Long, L. E., Chesworth, R., Huang, X.-F., Wong, A., Spiro, A., McGregor,
I. S., . . . Karl, T. (2012). Distinct Neurobehavioural Effects of
Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice. PLoS
One, 7 (4), e34129. doi:10.1371/journal.pone.0034129
Luchicchi, A., & Pistis, M. (2012). Anandamide and
2-arachidonoylglycerol: pharmacological properties, functional features,
and emerging specificities of the two major endocannabinoids. Mol
Neurobiol, 46 (2), 374-392. doi:10.1007/s12035-012-8299-0
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S.,
Andreakos, E., Mechoulam, R., & Feldmann, M. (2000). The
nonpsychoactive cannabis constituent cannabidiol is an oral
anti-arthritic therapeutic in murine collagen-induced arthritis.Proceedings of the National Academy of Sciences, 97 (17),
9561-9566. doi:10.1073/pnas.160105897
MANDRUP-POULSEN, T. (2003). Beta Cell Death and Protection. Annals
of the New York Academy of Sciences, 1005 (1), 32-42.
doi:https://doi.org/10.1196/annals.1288.005
Manzanares, J., Julian, M. D., & Carrascosa, A. (2006). Role of the
Cannabinoid System in Pain Control and Therapeutic Implications for the
Management of Acute and Chronic Pain Episodes. Current
neuropharmacology, 4 (3), 239-257.
doi:http://dx.doi.org/10.2174/157015906778019527
Martin, E. I., Ressler, K. J., Binder, E., & Nemeroff, C. B. (2009).
The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and
Psychoneuroendocrinology. Psychiatric Clinics of North America,
32 (3), 549-575. doi:https://doi.org/10.1016/j.psc.2009.05.004
Martinez-Aguirre, C., Carmona-Cruz, F., Velasco, A. L., Velasco, F.,
Aguado-Carrillo, G., Cuellar-Herrera, M., & Rocha, L. (2020).
Cannabidiol Acts at 5-HT1A Receptors in the Human Brain: Relevance for
Treating Temporal Lobe Epilepsy. Frontiers in Behavioral
Neuroscience, 14 . doi:ARTN 611278
10.3389/fnbeh.2020.611278
Martínez-Pinilla, E., Varani, K., Reyes-Resina, I., Angelats, E.,
Vincenzi, F., Ferreiro-Vera, C., . . . Franco, R. (2017). Binding and
Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol
in Cannabinoid CB2 Receptors. Frontiers in Pharmacology, 8 (744).
doi:10.3389/fphar.2017.00744
Massi, P., Solinas, M., Cinquina, V., & Parolaro, D. (2013).
Cannabidiol as potential anticancer drug. British Journal of
Clinical Pharmacology, 75 (2), 303-312.
doi:https://doi.org/10.1111/j.1365-2125.2012.04298.x
Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., &
Parolaro, D. (2006). The non-psychoactive cannabidiol triggers caspase
activation and oxidative stress in human glioma cells. Cellular
and Molecular Life Sciences CMLS, 63 (17), 2057-2066.
doi:10.1007/s00018-006-6156-x
Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., &
Parolaro, D. (2004). Antitumor Effects of Cannabidiol, a Nonpsychoactive
Cannabinoid, on Human Glioma Cell Lines. Journal of Pharmacology
and Experimental Therapeutics, 308 (3), 838-845.
doi:10.1124/jpet.103.061002
McAllister, S. D., Christian, R. T., Horowitz, M. P., Garcia, A., &
Desprez, P.-Y. (2007). Cannabidiol as a novel inhibitor of Id-1 gene
expression in aggressive breast cancer cells. Molecular Cancer
Therapeutics, 6 (11), 2921-2927. doi:10.1158/1535-7163.mct-07-0371
McAllister, S. D., Murase, R., Christian, R. T., Lau, D., Zielinski, A.
J., Allison, J., . . . Desprez, P.-Y. (2011). Pathways mediating the
effects of cannabidiol on the reduction of breast cancer cell
proliferation, invasion, and metastasis. Breast Cancer Research
and Treatment, 129 (1), 37-47. doi:10.1007/s10549-010-1177-4
McKallip, R. J., Jia, W., Schlomer, J., Warren, J. W., Nagarkatti, P.
S., & Nagarkatti, M. (2006). Cannabidiol-Induced Apoptosis in Human
Leukemia Cells: A Novel Role of Cannabidiol in the Regulation of
p22<em><sup>phox</sup></em>
and Nox4 Expression. Molecular Pharmacology, 70 (3), 897-908.
doi:10.1124/mol.106.023937
McPartland, J. M., Glass, M., & Pertwee, R. G. (2007). Meta-analysis of
cannabinoid ligand binding affinity and receptor distribution:
interspecies differences. British journal of pharmacology,
152 (5), 583-593. doi:https://doi.org/10.1038/sj.bjp.0707399
Melzack, R., & Wall, P. D. (1965). Pain Mechanisms: A New Theory.Science, 150 (3699), 971-979. doi:10.1126/science.150.3699.971
Michelle G. Craske, Ph.D. ,, Scott L. Rauch, M.D. ,, Robert Ursano, M.D.
,, Jason Prenoveau, Ph.D. ,, Daniel S. Pine, M.D. , and, & Richard E.
Zinbarg, Ph.D. (2011). What Is an Anxiety Disorder? FOCUS, 9 (3),
369-388. doi:10.1176/foc.9.3.foc369
Millar, S. A., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2018).
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans.Frontiers in Pharmacology, 9 . doi:ARTN 1365
10.3389/fphar.2018.01365
Mills, S. E. E., Nicolson, K. P., & Smith, B. H. (2019). Chronic pain:
a review of its epidemiology and associated factors in population-based
studies. British Journal of Anaesthesia, 123 (2), e273-e283.
doi:10.1016/j.bja.2019.03.023
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005).
Treatments for schizophrenia: a critical review of pharmacology and
mechanisms of action of antipsychotic drugs. Molecular Psychiatry,
10 (1), 79-104. doi:10.1038/sj.mp.4001556
Mlost, J., Bryk, M., & Starowicz, K. (2020). Cannabidiol for Pain
Treatment: Focus on Pharmacology and Mechanism of Action.International Journal of Molecular Sciences, 21 (22). doi:ARTN
8870
10.3390/ijms21228870
Morales, P., Reggio, P. H., & Jagerovic, N. (2017). An Overview on
Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol.Frontiers in Pharmacology, 8 (422). doi:10.3389/fphar.2017.00422
Moreno, E., Cavic, M., Krivokuca, A., Casadó, V., & Canela, E. (2019).
The Endocannabinoid System as a Target in Cancer Diseases: Are We There
Yet? Frontiers in Pharmacology, 10 (339).
doi:10.3389/fphar.2019.00339
Mouslech, Z., & Valla, V. (2009). Endocannabinoid system: An overview
of its potential in current medical practice. Neuro endocrinology
letters, 30 2 , 153-179.
Mukhopadhyay, P., Mohanraj, R., Bátkai, S., & Pacher, P. (2008). CB1
Cannabinoid Receptor Inhibition: Promising Approach for Heart Failure?Congestive Heart Failure, 14 (6), 330-334.
doi:https://doi.org/10.1111/j.1751-7133.2008.00016.x
Murillo-Rodriguez, E., Blanco-Centurion, C., Sanchez, C., Daniele, P.,
& Shiromani, P. J. (2003). Anandamide Enhances Extracellular Levels of
Adenosine and Induces Sleep: An In Vivo Microdialysis Study.Sleep, 26 (8), 943-947. doi:10.1093/sleep/26.8.943
Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S. (2015).
Emerging drugs for the treatment of anxiety. Expert Opinion on
Emerging Drugs, 20 (3), 393-406. doi:10.1517/14728214.2015.1049996
Mustafa, N. (2015). TRPV1 Channel: A Potential Drug Target for Treating
Epilepsy. Current neuropharmacology, 13 (2), 239-247.
doi:http://dx.doi.org/10.2174/1570159X13666150216222543
Nemeroff, C. B. (2003). The role of GABA in the pathophysiology and
treatment of anxiety disorders. Psychopharmacology bulletin,
37 (4), 133-146.
Nichols, J. M., & Kaplan, B. L. F. (2020). Immune Responses Regulated
by Cannabidiol. Cannabis and Cannabinoid Research, 5 (1), 12-31.
doi:10.1089/can.2018.0073
Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons,
S., & Sansom, C. (2004). Initial experiences with medicinal extracts of
cannabis for chronic pain: Results from 34 ‘N of 1’ studies.Anaesthesia, 59 (5), 440-452.
doi:https://doi.org/10.1111/j.1365-2044.2004.03674.x
O’Sullivan, S. E., Sun, Y., Bennett, A. J., Randall, M. D., & Kendall,
D. A. (2009). Time-dependent vascular actions of cannabidiol in the rat
aorta. European Journal of Pharmacology, 612 (1), 61-68.
doi:https://doi.org/10.1016/j.ejphar.2009.03.010
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A.
(2017). The endocannabinoid system as a target for novel anxiolytic
drugs. Neuroscience & Biobehavioral Reviews, 76 , 56-66.
doi:https://doi.org/10.1016/j.neubiorev.2016.12.033
Pava, M. J., Makriyannis, A., & Lovinger, D. M. (2016). Endocannabinoid
Signaling Regulates Sleep Stability. PLoS One, 11 (3), e0152473.
doi:10.1371/journal.pone.0152473
Peng, J., & Li, Y.-J. (2010). The vanilloid receptor TRPV1: Role in
cardiovascular and gastrointestinal protection. European Journal
of Pharmacology, 627 (1), 1-7.
doi:https://doi.org/10.1016/j.ejphar.2009.10.053
Perez-Reyes, E. (2003). Molecular Physiology of Low-Voltage-Activated
T-type Calcium Channels. Physiological Reviews, 83 (1), 117-161.
doi:10.1152/physrev.00018.2002
Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of
three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and
Δ9-tetrahydrocannabivarin. British journal of pharmacology,
153 (2), 199-215. doi:https://doi.org/10.1038/sj.bjp.0707442
Philip McGuire, F.R.C.Psych., F.Med.Sci. ,, Philip Robson, M.R.C.P.,
F.R.C.Psych. ,, Wieslaw Jerzy Cubala, M.D., Ph.D. ,, Daniel Vasile,
M.D., Ph.D. ,, Paul Dugald Morrison, Ph.D., M.R.C.Psych. ,, Rachel
Barron, B.Vet.Med., M.R.C.V.S. ,, . . . Stephen Wright, F.R.C.P.,
F.F.P.M. (2018). Cannabidiol (CBD) as an Adjunctive Therapy in
Schizophrenia: A Multicenter Randomized Controlled Trial. American
Journal of Psychiatry, 175 (3), 225-231.
doi:10.1176/appi.ajp.2017.17030325
Piomelli, D. (2003). The molecular logic of endocannabinoid signalling.Nature Reviews Neuroscience, 4 (11), 873-884. doi:10.1038/nrn1247
PPARs and the Cardiovascular System. (2009). Antioxidants & Redox
Signaling, 11 (6), 1415-1452. doi:10.1089/ars.2008.2280
Quigley, C. (2005). The role of opioids in cancer pain. BMJ,
331 (7520), 825-829. doi:10.1136/bmj.331.7520.825
Ramer, R., & Hinz, B. (2008). Inhibition of Cancer Cell Invasion by
Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix
Metalloproteinases-1. JNCI: Journal of the National Cancer
Institute, 100 (1), 59-69. doi:10.1093/jnci/djm268
Ramer, R., Merkord, J., Rohde, H., & Hinz, B. (2010). Cannabidiol
inhibits cancer cell invasion via upregulation of tissue inhibitor of
matrix metalloproteinases-1. Biochemical Pharmacology, 79 (7),
955-966. doi:https://doi.org/10.1016/j.bcp.2009.11.007
Ramer, R., Rohde, A., Merkord, J., Rohde, H., & Hinz, B. (2010).
Decrease of Plasminogen Activator Inhibitor-1 May Contribute to the
Anti-Invasive Action of Cannabidiol on Human Lung Cancer Cells.Pharmaceutical Research, 27 (10), 2162-2174.
doi:10.1007/s11095-010-0219-2
Rao, K. V., & Faso, A. (2012). Chemotherapy-induced nausea and
vomiting: optimizing prevention and management. American health &
drug benefits, 5 (4), 232-240.
Ressler, K. J., & Nemeroff, C. B. (2000). Role of serotonergic and
noradrenergic systems in the pathophysiology of depression and anxiety
disorders. Depression and Anxiety, 12 (S1), 2-19.
doi:https://doi.org/10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi-Goffer, S.,
Fletcher, P., . . . Parker, L. (2012). Cannabidiol, a non-psychotropic
component of cannabis, attenuates vomiting and nausea-like behaviour via
indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal
raphe nucleus. British journal of pharmacology, 165 (8),
2620-2634. doi:https://doi.org/10.1111/j.1476-5381.2011.01621.x
Ross, H. R., Napier, I., & Connor, M. (2008). Inhibition of Recombinant
Human T-type Calcium Channels by
Δ<sup>9</sup>-Tetrahydrocannabinol
and Cannabidiol *. Journal of Biological Chemistry, 283 (23),
16124-16134. doi:10.1074/jbc.M707104200
Ruiz-Medina, J., Ledent, C., & Valverde, O. (2011). GPR3 orphan
receptor is involved in neuropathic pain after peripheral nerve injury
and regulates morphine-induced antinociception. Neuropharmacology,
61 (1), 43-50.
doi:https://doi.org/10.1016/j.neuropharm.2011.02.014
Russo, E. B. (2007). History of Cannabis and Its Preparations in Saga,
Science, and Sobriquet. Chemistry & Biodiversity, 4 (8),
1614-1648. doi:https://doi.org/10.1002/cbdv.200790144
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005). Agonistic
Properties of Cannabidiol at 5-HT1a Receptors. Neurochemical
Research, 30 (8), 1037-1043. doi:10.1007/s11064-005-6978-1
Russo, E. B., Guy, G. W., & Robson, P. J. (2007). Cannabis, Pain, and
Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a
Cannabis-Based Medicine. Chemistry & Biodiversity, 4 (8),
1729-1743. doi:https://doi.org/10.1002/cbdv.200790150
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N.-O.,
Leonova, J., . . . Greasley, P. J. (2007). The orphan receptor GPR55 is
a novel cannabinoid receptor. British journal of pharmacology,
152 (7), 1092-1101. doi:https://doi.org/10.1038/sj.bjp.0707460
Sativex®. Retrieved from
https://www.gwpharm.com/healthcare-professionals/sativex
Schuelert, N., & McDougall, J. J. (2011). The abnormal cannabidiol
analogue O-1602 reduces nociception in a rat model of acute arthritis
via the putative cannabinoid receptor GPR55. Neurosci Lett,
500 (1), 72-76. doi:10.1016/j.neulet.2011.06.004
Scuderi, C., De Filippis, D., Iuvone, T., Blasio, A., Steardo, A., &
Esposito, G. (2009). Cannabidiol in Medicine: A Review of its
Therapeutic Potential in CNS Disorders. Phytotherapy Research,
23 (5), 597-602. doi:10.1002/ptr.2625
Scuderi, C., Steardo, L., & Esposito, G. (2014). Cannabidiol Promotes
Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid
Expression in SHSY5YAPP+ Cells Through PPARγ Involvement.Phytotherapy Research, 28 (7), 1007-1013.
doi:https://doi.org/10.1002/ptr.5095
Seltzer, E. S., Watters, A. K., MacKenzie, D., Granat, L. M., & Zhang,
D. (2020). Cannabidiol (CBD) as a Promising Anti-Cancer Drug.Cancers, 12 (11), 3203.
Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in
Anxiety and Sleep: A Large Case Series. The Permanente journal,
23 , 18-041. doi:10.7812/TPP/18-041
Shannon, S., & Opila-Lehman, J. (2016). Effectiveness of Cannabidiol
Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress
Disorder: A Case Report. The Permanente journal, 20 (4), 16.
doi:10.7812/TPP/16-005
Shin, H.-S. (2006). T-type Ca2+ channels and absence epilepsy.Cell Calcium, 40 (2), 191-196.
doi:https://doi.org/10.1016/j.ceca.2006.04.023
Sholler, D. J., Schoene, L., & Spindle, T. R. (2020). Therapeutic
Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical
Trials and Human Laboratory Studies. Curr Addict Rep, 7 (3),
405-412. doi:10.1007/s40429-020-00326-8
Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E.
(2019). Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and
Security in Clinical Trials. Molecules, 24 (8). doi:ARTN 1459
10.3390/molecules24081459
SREEVALSAN, S., JOSEPH, S., JUTOORU, I., CHADALAPAKA, G., & SAFE, S. H.
(2011). Induction of Apoptosis by Cannabinoids in Prostate and Colon
Cancer Cells Is Phosphatase Dependent. Anticancer Research,
31 (11), 3799-3807.
Stanley, C. P., Hind, W. H., & O’Sullivan, S. E. (2013). Is the
cardiovascular system a therapeutic target for cannabidiol?British Journal of Clinical Pharmacology, 75 (2), 313-322.
doi:https://doi.org/10.1111/j.1365-2125.2012.04351.x
State Medical Marijuana/Cannabis Program Laws. (2021). Retrieved from
https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx
Steffens, S., & Pacher, P. (2012). Targeting cannabinoid receptor CB2
in cardiovascular disorders: promises and controversies. British
journal of pharmacology, 167 (2), 313-323.
doi:https://doi.org/10.1111/j.1476-5381.2012.02042.x
Suraev, A., Grunstein, R. R., Marshall, N. S., D’Rozario, A. L., Gordon,
C. J., Bartlett, D. J., . . . Hoyos, C. M. (2020). Cannabidiol (CBD) and
Delta(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder
(’CANSLEEP’ trial): protocol for a randomised, placebo-controlled,
double-blinded, proof-of-concept trial. Bmj Open, 10 (5), e034421.
doi:10.1136/bmjopen-2019-034421
Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M.,
Denovan-Wright, E. M., & Laprairie, R. B. (2019). Allosteric and
orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl
at the type 1 and type 2 cannabinoid receptors. British journal of
pharmacology, 176 (10), 1455-1469.
doi:https://doi.org/10.1111/bph.14440
Thiele, E. A., Bebin, E. M., Bhathal, H., Jansen, F. E., Kotulska, K.,
Lawson, J. A., . . . Group, G. S. (2021). Add-on Cannabidiol Treatment
for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A
Placebo-Controlled Randomized Clinical Trial. JAMA Neurology,
78 (3), 285-292. doi:10.1001/jamaneurol.2020.4607
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A.,
& Pertwee, R. G. (2007). Cannabidiol displays unexpectedly high potency
as an antagonist of CB1 and CB2 receptor agonists in vitro.British journal of pharmacology, 150 (5), 613-623.
doi:https://doi.org/10.1038/sj.bjp.0707133
Touw, M. (1981). The Religious and Medicinal Uses of Cannabis in China,
India and Tibet. Journal of Psychoactive Drugs, 13 (1), 23-34.
doi:10.1080/02791072.1981.10471447
Tovote, P., Fadok, J. P., & Lüthi, A. (2015). Neuronal circuits for
fear and anxiety. Nature Reviews Neuroscience, 16 (6), 317-331.
doi:10.1038/nrn3945
Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel,
R., . . . Wang, S.-J. (2015). A classification of chronic pain for
ICD-11. Pain, 156 (6), 1003-1007.
doi:10.1097/j.pain.0000000000000160
Tsuboi, K., Uyama, T., Okamoto, Y., & Ueda, N. (2018). Endocannabinoids
and related N-acylethanolamines: biological activities and metabolism.Inflammation and Regeneration, 38 (1), 28.
doi:10.1186/s41232-018-0086-5
Urits, I., Gress, K., Charipova, K., Habib, K., Lee, D., Lee, C., . . .
Viswanath, O. (2020). Use of cannabidiol (CBD) for the treatment of
chronic pain. Best Practice & Research Clinical Anaesthesiology,
34 (3), 463-477. doi:https://doi.org/10.1016/j.bpa.2020.06.004
Vasko, M. R. (2009). Inflammatory Pain. In M. D. Binder, N. Hirokawa, &
U. Windhorst (Eds.), Encyclopedia of Neuroscience (pp.
1952-1955). Berlin, Heidelberg: Springer Berlin Heidelberg.
Vigil, J. M., Stith, S. S., Diviant, J. P., Brockelman, F., Keeling, K.,
& Hall, B. (2018). Effectiveness of Raw, Natural Medical Cannabis
Flower for Treating Insomnia under Naturalistic Conditions.Medicines, 5 (3), 75.
Vilela, L. R., Lima, I. V., Kunsch, É. B., Pinto, H. P. P., de Miranda,
A. S., Vieira, É. L. M., . . . Moreira, F. A. (2017). Anticonvulsant
effect of cannabidiol in the pentylenetetrazole model: Pharmacological
mechanisms, electroencephalographic profile, and brain cytokine levels.Epilepsy & Behavior, 75 , 29-35.
doi:https://doi.org/10.1016/j.yebeh.2017.07.014
von Wrede, R., Helmstaedter, C., & Surges, R. (2021). Cannabidiol in
the Treatment of Epilepsy. Clinical Drug Investigation .
doi:10.1007/s40261-021-01003-y
Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S.,
& Gallily, R. (2006). Cannabidiol lowers incidence of diabetes in
non-obese diabetic mice. Autoimmunity, 39 (2), 143-151.
doi:10.1080/08916930500356674
Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., &
Gallily, R. (2008). Cannabidiol arrests onset of autoimmune diabetes in
NOD mice. Neuropharmacology, 54 (1), 244-249.
doi:https://doi.org/10.1016/j.neuropharm.2007.06.029
Wheless, J. W., Dlugos, D., Miller, I., Oh, D. A., Parikh, N., Phillips,
S., . . . Investigators, I.-.-S. (2019). Pharmacokinetics and
Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic
Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy.Cns Drugs, 33 (6), 593-604. doi:10.1007/s40263-019-00624-4
White, C. M. (2019). A Review of Human Studies Assessing Cannabidiol’s
(CBD) Therapeutic Actions and Potential. Journal of Clinical
Pharmacology, 59 (7), 923-934. doi:10.1002/jcph.1387
Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K.,
Greasley, P. J., . . . Rogers, M. J. (2009). The putative cannabinoid
receptor GPR55 affects osteoclast function in vitro and bone mass in
vivo. Proceedings of the National Academy of Sciences, 106 (38),
16511-16516. doi:10.1073/pnas.0902743106
Wu, H.-Y., Chu, R.-M., Wang, C.-C., Lee, C.-Y., Lin, S.-H., & Jan,
T.-R. (2008). Cannabidiol-induced apoptosis in primary lymphocytes is
associated with oxidative stress-dependent activation of caspase-8.Toxicology and Applied Pharmacology, 226 (3), 260-270.
doi:https://doi.org/10.1016/j.taap.2007.09.012
Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S.-R., Willenbring, D., .
. . Zhang, L. (2012). Cannabinoids suppress inflammatory and neuropathic
pain by targeting α3 glycine receptors. Journal of Experimental
Medicine, 209 (6), 1121-1134. doi:10.1084/jem.20120242
Yang, K.-H., Galadari, S., Isaev, D., Petroianu, G., Shippenberg, T. S.,
& Oz, M. (2010). The Nonpsychoactive Cannabinoid Cannabidiol Inhibits
5-Hydroxytryptamine<sub>3A</sub>
Receptor-Mediated Currents in <em>Xenopus
laevis</em> Oocytes. Journal of
Pharmacology and Experimental Therapeutics, 333 (2), 547-554.
doi:10.1124/jpet.109.162594
Yokoe, T., Hayashida, T., Nagayama, A., Nakashoji, A., Maeda, H., Seki,
T., . . . Kitagawa, Y. (2019). Effectiveness of Antiemetic Regimens for
Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic
Review and Network Meta-Analysis. The Oncologist, 24 (6),
e347-e357. doi:https://doi.org/10.1634/theoncologist.2018-0140
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimaraes, F. S. (1993).
Effects of Ipsapirone and Cannabidiol on Human Experimental Anxiety.Journal of Psychopharmacology, 7 (1), 82-88. doi:Doi
10.1177/026988119300700112
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995).
Antipsychotic effect of cannabidiol. The Journal of Clinical
Psychiatry, 56 (10), 485-486.
Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak,
J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017). Inverted
U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol
during Public Speaking in Real Life. Frontiers in Pharmacology,
8 (259). doi:10.3389/fphar.2017.00259